nature genetics

Probabilistic inference

P(A = 1) 0.5

Gene A

and can incorporate other data through network 'priors'⁵.

Information flow through pathways is modeled through

differential equations or biophysical simulations, which

predict biological outcomes and are fit to measurements

and reaction kinetics^{3,6}. Tools: <u>SBW</u>, <u>Cell Designer</u>, <u>Copasi</u>

P(B = 1) 0.5

Gene B

0 0.9 1 0.05

0.0 0.0

0 1 0.2

1 0 0.1 1 1 0.95

Classification methods

(e.g. logistic regression)

measurements to learn

functional links between

weigh many different

properties⁴. Bayesian

networks use changing

molecular states over

identify direct causal

Tools: <u>Arachne</u>, <u>Banjo</u>

perturbations or time to

relationships among genes

Network dynamics and fluxes

proteins or other

Systems biology is the study of biology through systematic perturbation, equations and data visualization. These integrative approaches chart global read-out of the multifaceted response and integration of these the key components and interactions of biological systems over scales data to formulate predictive models¹. Here, we highlight the key steps ranging from single pathways to whole cells to entire populations of in the systems biology approach, with a focus on how global data sets individuals. Major applications of systems biology to biomedical are assembled into models of system structure and function. Techniques research are to identify genetic risk factors for disease, allow for for model assembly span many layers of abstraction, including statistical model-based personalized diagnostics and treatment regimens and mining, alignment across data sets, probabilistic inference, differential suggest new avenues for drug discovery.

Model assembly by data synthesis and integration

Statistical mining

Data filtering and clustering

The most basic form of data integration is to identify statistical overlap between data sets. Another statistical method is clustering, which groups molecules with similar profiles. 'Co-clustering' uses multiple integrated data

sets (e.g., mRNA expression & protein networks). Tools: <u>GenePattern</u>, <u>Cluster</u>, <u>ITreeview</u>, <u>MeV</u>

Functional enrichment

Outstanding measurements define gene sets which can be integrated with databases of known gene functions or pathways, indicating statistically enriched categories. Tools: DAVID, BiNGO, GSEA

Gene

Perturbations

• Chemicals/

- small molecules
- Genetic mutations/ RNAi
- Natural variation
- Changing environments
- Shifting time

Data alignment

Cross-species

Molecular sequences, states or interactions are aligned across species to identify conserved and diverged clusters. Tools: BLAST, NetworkBLAST (right), <u>IsoRankN</u>

Cross-data type

such as mRNA versus protein profiles or networks of

physical versus genetic interactions (right)². Molecular causes (e.g., genetic perturbations) are connected to effects (e.g., expression changes) through physical interaction paths³

Genome

Epigenome

Proteome


Physical

Genetic and

functional

e.g., humar Solid line Bold lines in

Alignment is also performed across multiple data types,



Molecular state measurements (nodes)

Whole-genome DNA

translation rate and

Protein abundances and

structure

microRNAs

Data types

Protein-protein

Protein-small molecule,

Synthetic lethality, epistasis

Cause-effect relationships

reaction fluxes

Transcriptome Transcript abundances,

Metabolome Metabolite profiling

Large-scale dataset types Technologies

Chromatin modifications and ChIP-seq, methyl-seq, DHS-chip

profiling

sequences, SNPs and CNVs microarrays

DNA sequencing, genotyping

DNA microarrays, RNA-seq

CAGE, GRO-seq, ribosome

NMR, mass spectrometry,

Mass spectrometry, liquid

Immuno-precipitation (IP),

two-hybrid, protein arrays,

co-affinity purification, yeast

kinase-substrate measurements

immuno-precipitation (ChIP),

Synthetic genetic arrays (SGA)

Genetic perturbation (gene

knockout, RNAi) followed by

cellular imaging); trans eQTLs

(expression quantitative trait loci)

phenotyping (microarrays,

combinatorial RNAi, population

DNA binding arrays

spectrometry

genetics

Isotope labeling, mass

hultiparameter FAC:

chromatography

Technologies

Protein–DNA, protein–RNA Genome-wide chromatin

annotations.

Molecular interaction measurements (edges)

Selected molecular

Model refinement and validation

An iterative process by which cellular models are refined based on the goodness-of-fit between predictions and data, giving rise to further experimentation.

Powerful data analysis, visualization and integration. Our bioinformatics tools are flexible and easy-to-use, implementing both in-house and publically available algorithms for rigorous analysis, visualization and

Through our collaborations with leading omics scientists, we are converting the latest technological advances into robust products that provide clear and reproducible results, leading you to answers you can trust. See the full picture with Agilent's multi omics solutions for integrated biology — visit <u>www.agilent.com/lifesciences/biology</u>.

References

genes. Science 306, 1555-1558 (2004). (MIT Press, Cambridge, MA, 2009)

Agilent Technologies Meeting the challenges of an integrated approach Agilent is uniquely positioned to help scientists overcome the technical and logistical challenges of an integrated approach to biology and generate the integration of your data. deeper insights that come from taking a broader view of biological systems. Simplified data collection. With products and expertise across the four major

omics — genomics, transcriptomics, proteomics and metabolomics — and automation platforms for more reproducible results with less hands-on time, we offer researchers the tools they need to obtain reliable, high-quality data.

Biological system

This system under perturbation can range in scale from molecular processes to cells, tissues, single organisms or up to populations of individuals.

Integrative systems biology

Trey Ideker and Sourav Bandyopadhyay

Network visualization

Data projection Probabilistic and mathematical modeling Sets network visuals, e.g., node and edge colors,

shapes and sizes, based on biological data, e.g., expression levels, functions (right) or knockout phenotypes.


Network layout


Force-directed layouts seek to minimize edge crossings through a physical simulation with edges as springs and with nodes as electrically charged particles.

Attribute-directed layouts use data attributes to attract nodes or edges to a layout region (right, proteins arranged by cellular compartment using Cerebral⁷).

Hierarchical layouts partition nodes into layers, e.g., master regulators above a set of regulated genes.

Tools: <u>Cytoscape</u>, <u>Osprey</u>, <u>VisAnt</u>, <u>Pajek</u>









Agilent Technologies

Pharmaceutical and clinical endpoints

A primary application of systems biology is to better understand and treat human disease. Network models will be central to next-generation drug development and patient management tools.

Systems level biomarkers Biomarkers are classically disease risk. In complex diseases, network models integrating a variety of risk value (right)⁸. Integrative and microRNA⁹ or use of metabolomic profiles¹⁰.





- Ideker, T., Galitski, T. & Hood, L. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet. 2, 343 (2001) Kelley, R. & Ideker, T. Systematic interpretation of genetic interactions using protein networks. Nat. Biotechnol. 23, 561-566 (2005) Herrgard, M. J., Covert, M. W. & Palsson, B. O. Reconciling gene expression data
- with known genome-scale regulatory network structures. Genome Res. 13, 2423–2434 Lee, I., Date, S. V., Adai, A. T. & Marcotte, E. M. A probabilistic functional network of yeast
- Koller, D. & Friedman, N. Probabilistic Graphical Models: Principles and Techniques.
- Janes, K. A. et al. A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 310, 1646-1653 (2005).
- Barsky, A., Gardy, J. L., Hancock, R. E. & Munzner, T. Cerebral: a Cytoscape plugin for layout of and interaction with biological networks using subcellular localization annotation Bioinformatics 23, 1040-1042 (2007) Chuang, H. Y., Lee, E., Liu, Y. T., Lee, D. & Ideker, T. Network-based classification of breast
- cancer metastasis. Mol. Syst. Biol. 3, 140 (2007) Lu. J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005)
- Sreekumar, A. et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. *Nature* **457**, 910–914 (2009) Ravasi, T. et al. An atlas of combinatorial transcriptional regulation in mouse and man.
- Cell 140, 744–752 (2010) Bild, A. H. *et al*. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353–357 (2006).
- Dressman, H. K. et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 25, 517–525 (2007)
- 14. lossifov, I., Zheng, T., Baron, M., Gilliam, T. C. & Rzhetsky, A. Genetic-linkage mapping of complex hereditary disorders to a whole-genome molecular-interaction network. Genome Res. 18, 1150–1162 (2008).
- Lage, K. et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat. Biotechnol. 25, 309–316 (2007). . Chen, Y. et al. Variations in DNA elucidate molecular networks that cause disease. Nature
- 452. 429-435 (2008
- Hannum, G. et al. Genome-wide association data reveal a global map of genetic interactions among protein complexes. PLoS Genet. 5, e1000782 (2009).
- Campillos, M. et al. Drug target identification using side-effect similarity. Science 321, 263-266 (2008)
- Gardner, T. S., di Bernardo, D., Lorenz, D. & Collins, J. J. Inferring genetic networks and identifying compound mode of action via expression profiling. *Science* **301**, 102–105 (2003) Vildirim, M. A., Goh, K. I., Cusick, M. E., Barabasi, A. L. & Vidal, M. Drug-target network. Nat. Biotechnol. 25, 1119-1126 (2007).

disease. They also identify pathways affected by an existing drug, either to predict the mode of action or to suggest drug repurposing in which drugs developed for one purpose can be reused to treat related diseases^{18–20}.

Acknowledgements

The authors are at the Departments of Medicine and Bioengineering, University of California, San Diego, California, USA. This work was supported by the National Institutes of Health (GM070743, RR018627) and the National Science Foundation (IIS0803937).

Edited by Orli Bahcall; copy edited by Erica Schultz; designed by Simon Fenwick. © 2010 Nature Publishing Group. http://www.nature.com/ng/extra/sysbio/index.html